Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes, according to ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with commercial insurance.

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment. Weight regain ...

Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients ...